147 related articles for article (PubMed ID: 35454892)
1. Next-Generation DNA Sequencing-Based Gene Panel for Diagnosis and Genetic Risk Stratification in Onco-Hematology.
Gargallo P; Molero M; Bilbao C; Stuckey R; Carrillo-Cruz E; Hermosín L; Pérez-López O; Jiménez-Velasco A; Soria E; Lázaro M; Carbonell P; Yáñez Y; Gómez I; Izquierdo-García M; Valero-García J; Ruiz C; Such E; Calabria I
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454892
[TBL] [Abstract][Full Text] [Related]
2. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Custom NGS Panel Validation for the Improvement of the Stratification of B-Acute Lymphoblastic Leukemia Patients.
Montaño A; Hernández-Sánchez J; Forero-Castro M; Matorra-Miguel M; Lumbreras E; Miguel C; Santos S; Ramírez-Maldonado V; Fuster JL; de Las Heras N; García-de Coca A; Sierra M; Dávila J; de la Fuente I; Olivier C; Olazabal J; Martínez J; Vega-García N; González T; Hernández-Rivas JM; Benito R
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32967112
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
[TBL] [Abstract][Full Text] [Related]
5. Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.
Gil JV; Such E; Sargas C; Simarro J; Miralles A; Pérez G; de Juan I; Palanca S; Avetisyan G; Santiago M; Fuentes C; Fernández JM; Vicente AI; Romero S; Llop M; Barragán E
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901871
[TBL] [Abstract][Full Text] [Related]
6. Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.
Izevbaye I; Liang LY; Mather C; El-Hallani S; Maglantay R; Saini L
J Mol Diagn; 2020 Feb; 22(2):208-219. PubMed ID: 31751678
[TBL] [Abstract][Full Text] [Related]
7. Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.
Leung B; Aung H; Nandini A; Abdulrasool G; Lau C; Seymour L
J Mol Diagn; 2024 May; 26(5):399-412. PubMed ID: 38367765
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
9. Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations.
Chicano M; Carbonell D; Suárez-González J; Lois S; Ballesteros-Culebras M; Andrés-Zayas C; Muñiz P; Rodríguez-Macias G; Bastos-Oreiro M; Font P; Ballesteros M; Kwon M; Anguita J; Díez-Martín JL; Buño I; Martínez-Laperche C
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203905
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive NGS Panel Validation for the Identification of Actionable Alterations in Adult Solid Tumors.
Martínez-Fernández P; Pose P; Dolz-Gaitón R; García A; Trigo-Sánchez I; Rodríguez-Zarco E; Garcia-Ruiz M; Barba I; Izquierdo-García M; Valero-Garcia J; Ruiz C; Lázaro M; Carbonell P; Gargallo P; Méndez C; Ríos-Martín JJ; Palmeiro-Uriach A; Camarasa-Lillo N; Forteza-Vila J; Calabria I
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33947144
[TBL] [Abstract][Full Text] [Related]
11. Analytical Validation of an Automated Semiconductor-Based Next-Generation Sequencing Assay for Detection of DNA and RNA Alterations in Myeloid Neoplasms.
Zbieranski N; Insuasti-Beltran G
J Mol Diagn; 2024 Jan; 26(1):29-36. PubMed ID: 37879438
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Molecular Investigations in Lysosomal Diseases: Clinical Integration of a Comprehensive Targeted Panel.
Sudrié-Arnaud B; Snanoudj S; Dabaj I; Dranguet H; Abily-Donval L; Lebas A; Vezain M; Héron B; Marie I; Duval-Arnould M; Marret S; Tebani A; Bekri S
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33673364
[TBL] [Abstract][Full Text] [Related]
13. Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia.
Vosberg S; Herold T; Hartmann L; Neumann M; Opatz S; Metzeler KH; Schneider S; Graf A; Krebs S; Blum H; Baldus CD; Hiddemann W; Spiekermann K; Bohlander SK; Mansmann U; Greif PA
Genes Chromosomes Cancer; 2016 Jul; 55(7):553-67. PubMed ID: 27015608
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of next generation sequencing based 35-gene hereditary cancer panel.
Chan W; Lee M; Yeo ZX; Ying D; Grimaldi KA; Pickering C; Yang MMS; Sundaram SK; Tzang LCH
Hered Cancer Clin Pract; 2020; 18():9. PubMed ID: 32368312
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
[TBL] [Abstract][Full Text] [Related]
16. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of copy number variant detection from panel-based next-generation sequencing data.
Yao R; Yu T; Qing Y; Wang J; Shen Y
Mol Genet Genomic Med; 2019 Jan; 7(1):e00513. PubMed ID: 30565893
[TBL] [Abstract][Full Text] [Related]
18. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of a Next-Generation Sequencing Panel for Syndromic and Nonsyndromic Hearing Loss.
Butz M; McDonald A; Lundquist PA; Meyer M; Harrington S; Kester S; Stein MI; Mistry NA; Zimmerman Zuckerman E; Niu Z; Schimmenti L; Hasadsri L; Boczek NJ
J Appl Lab Med; 2020 May; 5(3):467-479. PubMed ID: 32445360
[TBL] [Abstract][Full Text] [Related]
20. A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms.
Liquori A; Lesende I; Palomo L; Avetisyan G; Ibáñez M; González-Romero E; Boluda-Navarro M; Morote-Faubel M; Garcia-Ruiz C; Martinez-Valiente C; Santiago-Balsera M; Gomez-Seguí I; Sanjuan-Pla A; Sanz MA; Sanz G; Solé F; Such E; Cervera J
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33919541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
